Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma.
Cervical cancer is mainly associated with HPV genotype 16 infection. Recombinant measles virus (rMV) expressing HPV genotype 16 L1 capsid protein was generated by construction of an antigenomic plasmid, followed by rescue using the human "helper" cell line 293-3-46. In cell cultures the recombinant MV-L1 virus replicated practically as efficiently as the standard attenuated MV established as commercial vaccine, devoid of the transgene. The high genetic stability of MVb2-L1 was confirmed by 10 serial viral transfers in cell culture. In transgenic mice expressing the MV receptor CD46 the recombinant induced strong humoral immune responses against both MV and HPV; the antibodies against L1 exhibited mainly neutralizing capacity. Our data suggest that MV is a promising vehicle for development of inexpensive and efficient vaccines protecting from HPV infection.
Cantarella
Giuseppina
G
Etna Biotech srl, Catania, Italy.
Liniger
Matthias
M
Zuniga
Armando
A
Schiller
John T
JT
Billeter
Martin
M
Naim
Hussein Y
HY
Glueck
Reinhard
R
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001483:Base Sequence; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D002522:Chlorocebus aethiops; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D008459:Measles virus / Q000235:genetics*; D051379:Mice; D008969:Molecular Sequence Data; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000276:immunology*; D014709:Vero Cells; D014779:Virus Replication
D000914:Antibodies, Viral; D036022:Capsid Proteins; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; C063317:L1 protein, Human papillomavirus type 16